According to a recent report published by Grand View Research Inc.,product approval initiativesis likely to accelerate market expansion.
According to a report, “Enzymatic Wound Debridement Market Size, Share, & Trend Analysis Report By Product (Papain Product, Collagenase Product), By End Use (Hospitals, Homecare), And Segment Forecasts, 2019 – 2026”, published by Grand View Research, Inc. The global enzymatic wound debridement market size is expected to reach USD 1.10 billion by 2026, registering a CAGR of 5.8%, as per a new report by Grand View Research Inc.The increasing incidence of chronic diseases and the introduction of technologically advanced products are factoring the enzymatic wound debridement market growth.

Researchers and industry players have undertaken several initiatives for developing technologically advanced products. Collagenase-based enzymatic wound debridement products are majorly used for chronic & acute wounds treatment. Such products are gaining acceptance and has fueled the introduction of several technologically advanced products are being introduced in the market. For instance, NexoBrid (NXB), previously referred to as Debriding Gel Dressing (DGD)—which is derived from pineapple Bromelain group of enzymes-was introduced in 2017. NXB is an enzymatic wound debriding drug that can be effectively used in treating deep burn wounds.
New products are receiving government approvals for further commercialization. For instance, in May 2019, Vericel Corporation entered into a supply agreement and exclusive license with Medi Wound Ltd. to capitalize their product called Nexo Bridin North America. The Nexo Bridreceived approval in the U.S., European Union, and other international markets.
Click the link below:
https://www.grandviewresearch.com/industry-analysis/enzymatic-wound-debridement-market
Enzymatic Wound Debridement Market Report Highlights
- According to the WHO, an estimated 180 000 deaths occur every year due to severe burns in middle- and low-income countries and 30,000 people suffer new burns globally, some are severe enough to warrant immediate medical attention. Increasing number of accidents has resulted in a considerable growth of the market products
- Market giants have entered into strategic alliances to enhance product innovation capabilities and stay ahead of the market competition. In June 2019, MediWound launched EscharEx® under the U.S. Clinical Development Program as the company’s topical biological drug candidate for hard-to-heal wounds. The company followed the pre-defined interim assessment of enzymatic and autolytic debridement to ensure the efficacy, safety, and clinical benefit of EscharEx
- The acute wounds segmentaccounted for the highest revenue share in 2018. They include lacerations, burns abrasions, incisions, puncture wounds, etc. and is driven by the increasing number of burn injuries worldwide
- Collagenase-based enzymatic wound debridement product segment dominated the market in 2018. Collagenase-based creams, ointments, and gels are widely used for debridement of necrotic tissue from pressure ulcers, venous leg ulcers, burn wounds, and partial-thickness burns
- North America led the global market in 2018 due to rise in sports-related injuries and road accidents








